Evidence map›Paper›PMID 31729619›Full record

ArticleDigestive diseases and sciences2020

Intraperitoneal Treatment of Kisspeptin Suppresses Appetite and Energy Expenditure and Alters Gastrointestinal Hormones in Mice.

Tien S Dong, John P Vu, Suwan Oh, Daniel Sanford, Joseph R Pisegna, Patrizia Germano

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tien S DongThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. tsdong@mednet.ucla.edu.ORCID 0000-0003-0105-8063
John P VuDivision of Gastroenterology, Hepatology and Parenteral Nutrition, Department of Medicine and Human Genetics, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Suwan OhDivision of Gastroenterology, Hepatology and Parenteral Nutrition, Department of Medicine and Human Genetics, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Daniel SanfordDivision of Gastroenterology, Hepatology and Parenteral Nutrition, Department of Medicine and Human Genetics, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Joseph R PisegnaDivision of Gastroenterology, Hepatology and Parenteral Nutrition, Department of Medicine and Human Genetics, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Patrizia GermanoResearch Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
VA Greater Los Angeles Healthcare System · USUniversity of California, Los Angeles · USAbbVie (United States) · US

Funding

GASTROENTEROLOGYT32DK007180 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JENSEN, DENNIS MICHAEL · 1986 to 2025
$10.0M
NIDDK NIH HHS T32 DK007180
6 · The paper itself

Abstract

backgroundKisspeptin is a neuropeptide that plays an integral role in the regulation of energy intake and reproduction by acting centrally on the hypothalamus-pituitary-gonadal axis. Our current study explores for the first time the effects of a pharmacological treatment of intraperitoneal kisspeptin-10 on murine feeding behavior, respirometry parameters, energy balance, and metabolic hormones.

methodsTwo groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle. Microstructure of feeding and drinking behavior, respirometry gases, respiratory quotient (RQ), total energy expenditure (TEE), metabolic hormones, oral glucose tolerance, and lipid profiles were measured.

resultsIntraperitoneal treatment with kisspeptin-10 caused a significant reduction in food intake, meal frequency, meal size, and eating rate. Kisspeptin-10 significantly decreased TEE during both the dark and light phase cycles, while also increasing the RQ during the dark-phase cycle. In addition, mice injected with kisspeptin-10 had significantly higher plasma levels of insulin (343.8 pg/ml vs. 106.4 pg/ml; p = 0.005), leptin (855.5 pg/ml vs. 173.1 pg/ml; p = 0.02), resistin (9411.1 pg/ml vs. 4116.5 pg/ml; p = 0.001), and HDL (147.6 mg/dl vs 97.1 mg/dl; p = 0.04).

conclusionA pharmacological dose of kisspeptin-10 significantly altered metabolism by suppressing food intake, meal size, eating rate, and TEE while increasing the RQ. These changes were linked to increased levels of insulin, leptin, resistin, and HDL. The current results suggest that a peripheral kisspeptin treatment could alter metabolism and energy homeostasis by suppressing appetite, food intake, and fat accumulation.

Indexed as

AnimalsAppetiteCholesterol, HDLDrug Evaluation, PreclinicalEnergy MetabolismFeeding BehaviorFemaleGastrointestinal HormonesInjections, IntraperitonealKisspeptinsMaleMice, Inbred C57BLMotor ActivityCholesterol, HDLGastrointestinal HormonesKISS1 protein, humanKisspeptinsInsulinKisspeptin-10LeptinMetabolismResistin

Identifiers

PMID31729619
OpenAlexW2988319756

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.